汇宇制药-W
(688553)
| 流通市值：46.69亿 | | | 总市值：57.57亿 |
| 流通股本：3.44亿 | | | 总股本：4.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 239,052,524.64 | 1,094,382,336.85 | 851,844,303.21 | 532,202,419.92 |
| 营业收入 | 239,052,524.64 | 1,094,382,336.85 | 851,844,303.21 | 532,202,419.92 |
| 二、营业总成本 | 209,039,659.41 | 1,006,585,170.23 | 741,467,771.85 | 483,098,243.55 |
| 营业成本 | 39,158,727.24 | 181,511,412.22 | 143,515,070.74 | 94,289,969.57 |
| 税金及附加 | 1,225,270.8 | 7,910,228.78 | 4,728,199.32 | 3,137,120.56 |
| 销售费用 | 93,561,450.97 | 431,089,814.91 | 326,663,876.33 | 204,990,084.52 |
| 管理费用 | 22,137,967.87 | 80,468,747.88 | 55,233,228.17 | 37,324,084.33 |
| 研发费用 | 61,856,632.31 | 327,724,906.96 | 225,022,804.88 | 147,779,271.51 |
| 财务费用 | -8,900,389.78 | -22,119,940.52 | -13,695,407.59 | -4,422,286.94 |
| 其中:利息费用 | 1,797,026.94 | 12,403,269.02 | 9,988,609.6 | 6,996,443.62 |
| 其中:利息收入 | 8,480,289.7 | 36,416,228.9 | -23,234,579.08 | 12,073,510.24 |
| 加:公允价值变动收益 | -81,849,444.82 | 239,856,212.2 | 115,503,121.76 | - |
| 加:投资收益 | 703,249.21 | 13,815,175.53 | 15,370,176.68 | 8,583,268.7 |
| 资产处置收益 | - | -301,236.61 | - | - |
| 资产减值损失(新) | -1,685,087.14 | -14,813,594.43 | -9,604,942.95 | -259,603.59 |
| 信用减值损失(新) | -217,008.62 | 1,810,843.07 | -1,595,659.56 | -1,729,744.99 |
| 其他收益 | 9,215,405.84 | 20,267,889.31 | 14,368,447.3 | 9,335,042.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -43,820,020.3 | 348,432,455.69 | 244,417,674.59 | 65,033,138.74 |
| 加:营业外收入 | 716,722 | 7,588,498.18 | 7,232,262.6 | 6,545,362.49 |
| 减:营业外支出 | 30,886.72 | 6,322,077.17 | 1,597,389.62 | 245,209.97 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -43,134,185.02 | 349,698,876.7 | 250,052,547.57 | 71,333,291.26 |
| 减:所得税费用 | -16,448,635.67 | 33,801,654.4 | 29,287,036.19 | 9,128,282.38 |
| 六、净利润 | -26,685,549.35 | 315,897,222.3 | 220,765,511.38 | 62,205,008.88 |
| 持续经营净利润 | -24,119,744.57 | 315,897,222.3 | 220,765,511.38 | 62,205,008.88 |
| 归属于母公司股东的净利润 | -25,626,485.3 | 325,390,295.3 | 227,352,384.74 | 65,213,416.74 |
| 少数股东损益 | -1,059,064.05 | -9,493,073 | -6,586,873.36 | -3,008,407.86 |
| (一)基本每股收益 | -0.06 | 0.77 | 0.54 | 0.15 |
| (二)稀释每股收益 | -0.06 | 0.77 | 0.54 | 0.15 |
| 八、其他综合收益 | -602,978.36 | 910,833.69 | 1,952,448.71 | 173,085.02 |
| 归属于母公司股东的其他综合收益 | -602,978.36 | 910,833.69 | 1,952,448.71 | 173,085.02 |
| 九、综合收益总额 | -27,288,527.71 | 316,808,055.99 | 222,717,960.09 | 62,378,093.9 |
| 归属于母公司股东的综合收益总额 | -26,229,463.66 | 326,301,128.99 | 229,304,833.45 | 65,386,501.76 |
| 归属于少数股东的综合收益总额 | -1,059,064.05 | -9,493,073 | -6,586,873.36 | -3,008,407.86 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |